Vaxart Inc. (VXRT)

0.37
NASDAQ : Health Technology
Prev Close 0.38
Day Low/High 0.37 / 0.38
52 Wk Low/High 0.25 / 5.00
Avg Volume 650.00K
Exchange NASDAQ
Shares Outstanding 38.35M
Market Cap 14.44M
EPS -2.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Vaxart's Tableted Oral Bivalent Norovirus Vaccine Meets Primary And Secondary Endpoints In Phase 1b Study

Vaxart's Tableted Oral Bivalent Norovirus Vaccine Meets Primary And Secondary Endpoints In Phase 1b Study

Both norovirus vaccines induced substantial immune responses with no indication of immunological interference when administered concurrently Phase 2-ready oral norovirus vaccine targets potential $3B+ market opportunity SOUTH SAN FRANCISCO, Calif.

Vaxart To Present At The H.C. Wainwright 21st Annual Global Investment Conference

Vaxart To Present At The H.C. Wainwright 21st Annual Global Investment Conference

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Wouter Latour, M.

Vaxart Announces Second Quarter 2019 Financial Results And Provides Corporate Update

Vaxart Announces Second Quarter 2019 Financial Results And Provides Corporate Update

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced financial results for the second quarter ended June 30, 2019.

Vaxart Enters Into Research Collaboration With Janssen To Evaluate Oral Universal Influenza Vaccine

Vaxart Enters Into Research Collaboration With Janssen To Evaluate Oral Universal Influenza Vaccine

Vaxart, Inc., (Vaxart), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it has entered into a research collaboration agreement with Janssen Vaccines...

Vaxart To Present At ASM Microbe 2019

Vaxart To Present At ASM Microbe 2019

Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Roberto Mateo, Ph.

New Publication In Vaccine Highlights Preclinical Results Of Vaxart's Mucosal Chikungunya Vaccine

New Publication In Vaccine Highlights Preclinical Results Of Vaxart's Mucosal Chikungunya Vaccine

Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the publication of the comprehensive results from a preclinical trial of its...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: FWONA, FWONK, HMN Downgrades: AAME, ABEV, ABR, ALKS, CCS, EXP, PKE, PTR, SCSC, SILC, SMLP, SNMP, TR, TSE Initiations: LAZY, VXRT Read on to get TheStreet Quant Ratings' detailed report:

Vaxart Announces First Quarter 2019 Financial Results And Provides Corporate Update

Vaxart Announces First Quarter 2019 Financial Results And Provides Corporate Update

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced financial results for the first quarter ended March 31, 2019.

Vaxart Doses First Patient In Randomized Cohort Of Bivalent Norovirus Vaccine Phase 1b Clinical Trial

Vaxart Doses First Patient In Randomized Cohort Of Bivalent Norovirus Vaccine Phase 1b Clinical Trial

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced it has started dosing subjects in the randomized cohort of the Phase 1b bivalent norovirus...

Vaxart To Present At The 29th European Congress Of Clinical Microbiology & Infectious Diseases

Vaxart To Present At The 29th European Congress Of Clinical Microbiology & Infectious Diseases

Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Roberto Mateo, Ph.

Vaxart Announces Pricing Of Underwritten Public Offering

Vaxart Announces Pricing Of Underwritten Public Offering

Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biopharmaceutical company focused on the development of oral recombinant vaccines based on its proprietary oral vaccine platform, today announced the pricing of an underwritten public offering of 9,090,010...

Vaxart To Present At Global Medical Meetings In April

Vaxart To Present At Global Medical Meetings In April

Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced participation in two upcoming global medical meetings in April.

Vaxart Completes Dosing Of The Lead-In Cohort In Bivalent Norovirus Vaccine Phase 1b Clinical Trial

Vaxart Completes Dosing Of The Lead-In Cohort In Bivalent Norovirus Vaccine Phase 1b Clinical Trial

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the completion of dosing of the lead-in cohort in the Phase 1b bivalent norovirus vaccine...

Vaxart Announces Closing Of Registered Direct Offering Of Common Stock

Vaxart Announces Closing Of Registered Direct Offering Of Common Stock

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the closing of its previously announced registered direct offering of 1,200,000 shares of...

Vaxart Announces $3 Million Registered Direct Offering Priced At-the-Market

Vaxart Announces $3 Million Registered Direct Offering Priced At-the-Market

Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biopharmaceutical company focused on the development of oral recombinant vaccines based on its proprietary oral vaccine platform, today announced that it has entered into definitive agreements with certain...

Vaxart Announces Initiation Of Bivalent Norovirus Vaccine Phase 1b Clinical Trial

Vaxart Announces Initiation Of Bivalent Norovirus Vaccine Phase 1b Clinical Trial

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the initiation of a Phase 1b bivalent norovirus vaccine clinical trial.

Vaxart Announces Fourth Quarter And Year-End 2018 Financial Results And Provides Corporate Update

Vaxart Announces Fourth Quarter And Year-End 2018 Financial Results And Provides Corporate Update

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced financial results for the fourth quarter and full year ended December 31, 2018.

Vaxart To Present At World Vaccine And Immunotherapy Congress West Coast 2018

Vaxart To Present At World Vaccine And Immunotherapy Congress West Coast 2018

Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Sean Tucker, Ph.

Vaxart Announces Third Quarter 2018 Financial Results And Provides Corporate Update

Vaxart Announces Third Quarter 2018 Financial Results And Provides Corporate Update

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced financial results for the third quarter ended September 30, 2018 and provided a corporate...

New Data From Phase 2 Flu Challenge Study Demonstrates Vaxart's Oral H1 Flu Vaccine Generated Protective Mucosal Immunity

New Data From Phase 2 Flu Challenge Study Demonstrates Vaxart's Oral H1 Flu Vaccine Generated Protective Mucosal Immunity

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced it will present new data from the Phase 2 Challenge Study of its H1 influenza oral tablet vaccine...

Vaxart Announces Second Quarter 2018 Financial Results And Corporate Update

Vaxart Announces Second Quarter 2018 Financial Results And Corporate Update

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced financial results for the second quarter ended June 30, 2018 and provided a corporate...

Vaxart Announces Publication Of The Phase 1 Results Of Its Oral Norovirus Tablet Vaccine In Journal Of Clinical Investigation Insight

Vaxart Announces Publication Of The Phase 1 Results Of Its Oral Norovirus Tablet Vaccine In Journal Of Clinical Investigation Insight

Vaxart, Inc. (Nasdaq:VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced publication of the comprehensive results of the previously disclosed Phase 1...

Oral RSV Vaccine - Preclinical Data Published In Vaccine

Oral RSV Vaccine - Preclinical Data Published In Vaccine

Vaxart, Inc. (Nasdaq:VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced publication of the preclinical results of its oral F-protein based...

Vaxart Reports Topline Results From Phase 2 Trial Of Teslexivir™ For The Treatment Of Condyloma

Vaxart Reports Topline Results From Phase 2 Trial Of Teslexivir™ For The Treatment Of Condyloma

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today reported the topline results from a Phase 2 clinical trial evaluating the safety and efficacy of an...

Vaxart To Present At The Jefferies 2018 Global Healthcare Conference

Vaxart To Present At The Jefferies 2018 Global Healthcare Conference

Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Wouter Latour, M.

Vaxart To Present At ASM Microbe 2018

Vaxart, Inc. (NASDAQ:VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Roberto Mateo, Ph.

Vaxart Announces First Quarter 2018 Financial Results And Corporate Update

Vaxart Announces First Quarter 2018 Financial Results And Corporate Update

Vaxart, Inc. (Nasdaq:VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced financial results for the first quarter ended March 31, 2018 and provided a...

Vaxart Appoints Dr. David Taylor As Chief Medical Officer

Vaxart Appoints Dr. David Taylor As Chief Medical Officer

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the appointment of David Taylor, M.

TheStreet Quant Rating: D- (Sell)